| 000 | 01731 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517081024.0 | ||
| 264 | 0 | _c20161220 | |
| 008 | 201612s 0 0 eng d | ||
| 022 | _a1872-9096 | ||
| 024 | 7 |
_a10.1016/j.antiviral.2016.02.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAndouard, D | |
| 245 | 0 | 0 |
_aContrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis. _h[electronic resource] |
| 260 |
_bAntiviral research _cMay 2016 |
||
| 300 |
_a115-119 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xpharmacology |
| 650 | 0 | 4 | _aChromosomes, Artificial, Bacterial |
| 650 | 0 | 4 |
_aCytomegalovirus _xdrug effects |
| 650 | 0 | 4 |
_aCytosine _xpharmacology |
| 650 | 0 | 4 |
_aDNA, Viral _xgenetics |
| 650 | 0 | 4 |
_aDNA-Directed DNA Polymerase _xchemistry |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 |
_aFoscarnet _xpharmacology |
| 650 | 0 | 4 |
_aGanciclovir _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Molecular |
| 650 | 0 | 4 | _aMutagenesis |
| 650 | 0 | 4 |
_aOrganophosphonates _xpharmacology |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 | _aPoint Mutation |
| 650 | 0 | 4 | _aProtein Domains |
| 650 | 0 | 4 |
_aViral Proteins _xchemistry |
| 700 | 1 | _aMazeron, M-C | |
| 700 | 1 | _aLigat, G | |
| 700 | 1 | _aCouvreux, A | |
| 700 | 1 | _aPouteil-Noble, C | |
| 700 | 1 | _aCahen, R | |
| 700 | 1 | _aYasdanpanah, Y | |
| 700 | 1 | _aDeering, M | |
| 700 | 1 | _aViget, N | |
| 700 | 1 | _aAlain, S | |
| 700 | 1 | _aHantz, S | |
| 773 | 0 |
_tAntiviral research _gvol. 129 _gp. 115-119 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.antiviral.2016.02.004 _zAvailable from publisher's website |
| 999 |
_c25729078 _d25729078 |
||